Skip to main content

2. ToxGenSolutions BV identifies a 9 miRNA peripheral profile to identify individuals at risk for late-onset Alzheimer’s Disease years in advance

Skrevet af ToxGenSolutions BV d. . Uploaded i Breaking News.

14.02.2023

As part of an effort to drive the development of cutting-edge biomarkers and explore novel diagnostic technologies, ToxGenSolutions BV has identified a peripheral profile of 9 microRNAs (miRNAs) to identify individuals at risk for late-onset Alzheimer’s Disease (AD) years in advance.

The goal of the program is to diagnose late-onset Alzheimer’s Disease:

  1. Faster by turning the months/years it takes for the current diagnostic approach into hours.
  2. Cheaper by eliminating the dependence on expensive imaging.
  3. More accurate in the prodromal phase of the disease. Currently, nearly 50% of individuals diagnosed with mild cognitive impairment (MCI) do not develop dementia.
  4. Less invasive and more patient-friendly by replacing CSF sampling with a standard blood draw.

It is our pleasure to announce that the Diagnostics Accelerator at the Alzheimer’s Drug Discovery Foundation (ADDF) will support ToxGenSolutions BV in this endeavour.

Alzheimer's disease, peripheral biomarker profile

ToxGenSolutions BV

Erwin L Roggen (CEO): More than 25 years of industrial experience (including 15 years as a manager) in the development, implementation and use of animal-free methods; Self-employed since 2013 (www.3rsmc-aps.com) with the mission to valorise promising animal-free methods; Founder and co-owner (2011) of the listed company SenzaGen AB (Lund, Sweden) (www.senzagen.com), specialized in cell-based identification methods for allergens. profile: http://www.linkedin.com/profile/view?id=23021602&trk=tab_pro